<DOC>
	<DOCNO>NCT00095836</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . PURPOSE : Phase II trial study effectiveness gefitinib treat patient locally advance metastatic thyroid cancer respond iodine therapy .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Locally Advanced Metastatic Thyroid Cancer That Did Not Respond Iodine Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine all-measurable-disease response rate patient iodine-refractory locally advanced metastatic thyroid cancer treat gefitinib . Secondary - Determine toxicity drug patient . - Determine progression-free overall survival patient treated drug . OUTLINE : This open-label study . Patients receive oral gefitinib daily . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm thyroid cancer Metastatic locally advance disease Not amenable OR unresponsive refractory local therapy and/or radioactive iodine , depend cell type Medullary anaplastic thyroid carcinoma consider unresponsive basis histology alone Welldifferentiated papillary follicular thyroid carcinoma consider refractory evidence uptake radioactive iodine scanning OR tumor progress despite treatment radioactive iodine Measurable disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic AST ALT ≤ 3 time normal Bilirubin ≤ 1.5 time normal No unstable uncompensated hepatic disease Renal Creatinine ≤ Common Toxicity Criteria grade 2 No unstable uncompensated renal disease Cardiovascular No unstable uncompensated cardiac disease Pulmonary No clinically active interstitial lung disease Chronic , stable , asymptomatic radiographic change allow No unstable uncompensated respiratory disease Other No know severe hypersensitivity gefitinib excipients No severe uncontrolled systemic disease No significant clinical disorder laboratory find would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics No concurrent localregional radiotherapy primary disease site No concurrent radiotherapy bony CNS metastasis Surgery Completely heal prior oncologic major surgery Other Recovered prior anticancer therapy More 30 day since prior nonapproved investigational drug No concurrent use follow agent : Phenytoin Carbamazepine Barbiturates Rifampin Phenobarbital Hypericum perforatum ( St. John 's wort ) Systemic retinoids Cyclosporine Verapamil Diltiazem Nicardipine Nifedipine Nitrendipine Erythromycin Theophylline Ketoconazole Itraconazole Antihistamines ( e.g. , terfenadine astemizole ) No concurrent grapefruit grapefruit juice No concurrent systemic anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>stage III follicular thyroid cancer</keyword>
	<keyword>stage III papillary thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
</DOC>